Empagliflozin & Sitagliptin - Landmark Trials Revisited in 2026 Dr. Bhumika Maikhuri23 Feb 2026 10:30 AM ISTIn this episode of Diabetes Wellness Forum, titled, "Empagliflozin & Sitagliptin - Landmark Trials Revisited in 2026", Dr Nandita Mohan from...
Redefining Diabetes Management With Dapagliflozin and Sitagliptin FDC: An Early, Effective and Sustainable Option For T2D Management With Risk Factors Dr. Vaishali Deskhmukh12 Feb 2026 12:40 PM ISTType 2 diabetes in Indians follows a distinct and more aggressive trajectory, marked by higher insulin resistance, early Beta-cell dysfunction, lower...
Considering Triple Agents in Glucose Control - Application & Safety Considerations in 2026 Dr. Bhumika Maikhuri11 Feb 2026 11:00 AM ISTIn this episode of The Diabetes Wellness Forum, titled "Considering Triple Agents-Application & Safety Considerations in 2026," Dr Nandita Mohan...
SURPASS-2- Tirzepatide vs Semaglutide in Type 2 Diabetes Deeksha Bhandari4 Feb 2026 12:30 PM ISTKey Summary: In addition to meeting the primary objective of noninferiority to semaglutide in type 2 diabetes (T2D), tirzepatide, at a dose of...
Efficacy and Safety of Dapagliflozin-Vildagliptin in Indian T2DM Patients with CV Risk Factors Dr. Bhumika Maikhuri30 Jan 2026 12:58 PM ISTThe Fixed-Dose Combination (FDC) of Dapagliflozin 5 mg + Vildagliptin 50 mg demonstrated significant improvements in Glycemic Control, Metabolic...
Robust Glycemic Control & Cardio-Renal Protection: Meeting the Advanced Needs of Indian Uncontrolled T2D with Empagliflozin, Sitagliptin, Metformin Dr. Nilanjan Sengupta28 Jan 2026 12:45 PM ISTIndia has an estimated 90 million people living with T2D [1] amid rising obesity and doubled management costs. Uncontrolled T2DM and early-onset...
Importance of Early Aggressive Glucose Control - Approach in 2026 Dr. Bhumika Maikhuri15 Jan 2026 11:15 AM ISTIn this episode of The Diabetes Wellness Forum, titled "Importance of Early Aggressive Glucose Control-Approach in 2026," Dr Nandita Mohan from...
Integrating Low-Cost Interventions: Yoga and Walking Demonstrate Significant Glycemic Benefit in Type 2 Diabetes Dr. Bhumika Maikhuri18 Dec 2025 12:15 PM ISTA recent study found a substantial time-dependent decrease in acute blood glucose levels (FBS and PPBS) in patients with type 2 diabetes, with the...
Uncontrolled T2DM in India and Application of Trusted Molecules Empagliflozin, Sitagliptin, and Metformin Coming Together Dr. Sunil M Jain10 Dec 2025 11:13 AM ISTThe Growing Burden of Uncontrolled T2DM in India: The burden of diabetes in India has risen markedly, yet only around 7% of individuals with diagnosed...
Psoriasis linked to Risk of Diabetic Retinopathy in Type-2 Diabetes Mellitus Patients: Study Dr. Shravani Dali3 Dec 2025 10:15 AM ISTResearchers have found in a new study published in Diabetes Research and Clinical Practice that prior psoriasis in patients with type 2 diabetes...
Tirzepatide for Obesity: Highlights from the SURMOUNT-1 Trial Deeksha Bhandari2 Dec 2025 10:57 AM ISTThe SURMOUNT-1 trial evaluated Tirzepatide a dual GIP/GLP1 agonist, in individuals with overweight (BMI more than or equal to 27 with a comorbidity)...
Optimising Type 2 Diabetes Outcomes through Dapagliflozin and Sitagliptin FDC: A Gluco-Cardio-Renal Perspective Dr. Mayur Agrawal27 Nov 2025 11:15 AM ISTType 2 Diabetes (T2D) is a major public health challenge, with India ranking second globally in prevalence. [1] The coexistence of diabetes,...
